Abstract PO-169: Impacts of neighborhood characteristics and surgical treatment disparities on overall mortality in stage I renal cell carcinoma patients

2022 ◽  
Author(s):  
Alejandro Cruz ◽  
Faith Dickerson ◽  
Kathryn R. Pulling ◽  
Kyle Garcia ◽  
Francine C. Gachupin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Stage I ◽  
Neighborhood Characteristics ◽  
Treatment Disparities ◽  
Overall Mortality

scholarly journals MP67-15 SURGICAL TREATMENT FOR STAGE I RENAL CELL CARCINOMA: DOES TREATMENT FACILITY MATTER?

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Kyle plante ◽  
Telisa Stewart ◽  
Dongliang Wang ◽  
Thomas Schwaab ◽  
Gennady Bratslavsky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Stage I ◽  
Treatment Facility

506: A Risk-Adjusted Follow-up for Patients with Stage I and II Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 169-169
Author(s):  
Quoc-Dien Trinh ◽  
Pierre I. Karakiewicz ◽  
Thierry Lebeau ◽  
Dan Lewinshtein ◽  
Elie Antebi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Stage I

scholarly journals Renal Cell Carcinoma with Synchronous Metastasis to the Calcaneus and Metachronous Metastases to the Ovary and Gallbladder

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Jasper Decoene ◽  
Filip Ameye ◽  
Evelyne Lerut ◽  
Raymond Oyen ◽  
Hein Van Poppel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Review Of The Literature ◽  
Synchronous Metastasis ◽  
Renal Cell Carcinomas ◽  
Gallbladder Metastasis ◽  
Metachronous Metastases ◽  
Systemic Therapies

Renal cell carcinomas (RCCs) are known for their unpredictable metastatic pattern. We present the case of a 63-year-old woman who initially presented in 1992 with a metastasis in the left calcaneus that led to the discovery of RCC. In 1998, a new metastasis was found in the ovary. In 2008, the diagnosis of a gallbladder metastasis was made. All metastases were surgically removed; no additional systemic therapies were used. Aggressive surgical treatment can prolong the survival of patients with resectable metastases. Patterns of metastasis are discussed, and a brief review of the literature is given regarding each localization.

Multicentricity in Renal Cell Carcinoma: Can Primary Tumor Location Serve as a Co-Determinant of Surgical Treatment?

2002 ◽  
Vol 41 (3) ◽  
pp. 262-266 ◽  
Author(s):  
N. Melissourgos ◽  
K. Doumas ◽  
I. Messini ◽  
E. Papaliodi ◽  
N.G. Kastrinakis ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Tumor Location ◽  
Primary Tumor Location

Risk‐adjusted proposal for >60 months follow up after surgical treatment of organ‐confined renal cell carcinoma according to life expectancy

2018 ◽  
Vol 26 (3) ◽  
pp. 385-390 ◽  
Author(s):  
Sebastian K Frees ◽  
Mohammed M Kamal ◽  
Sebastian Nestler ◽  
Patrick MF Levien ◽  
Samir Bidnur ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Life Expectancy ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma

2018 ◽  
Vol 14 (2) ◽  
pp. 68-78 ◽  
Author(s):  
B. Ya. Alekseev ◽  
I. M. Shevchuk ◽  
A. D. Kaprin
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Surgical Treatment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Optimal Dosage ◽  
Second Line ◽  
Newly Diagnosed ◽  
Disease Prognosis ◽  
Metastatic Rcc

Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies worldwide. Approximately 25–30 % of newly diagnosed patients have metastatic RCC (mRCC), whereas in 20–30 % of cases, dissemination occurs after radical surgical treatment. The development of targeted and immunooncological agents in recent years significantly increased survival in patients with mRCC. However, clinicians faced a problem of choosing an optimal therapeutic regimen to achieve maximum effectiveness of the treatment. This article discusses the choice of second-line drugs for mRCC, advantages of axitinib and its optimal dosage, and efficacy of sunitinib depending on the disease prognosis.

scholarly journals Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e8096 ◽  
Author(s):  
Haiping Zhang ◽  
Jian Zou ◽  
Ying Yin ◽  
Bo Zhang ◽  
Yaling Hu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Differentially Expressed Genes ◽  
Renal Cell ◽  
Molecular Mechanisms ◽  
Clear Cell ◽  
Clinical Stage ◽  
Stage I ◽  
Differentially Expressed ◽  
Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is one of the most common and lethal types of cancer within the urinary system. Great efforts have been made to elucidate the pathogeny. However, the molecular mechanism of ccRCC is still not well understood. The aim of this study is to identify key genes in the carcinogenesis and progression of ccRCC. The mRNA microarray dataset GSE53757 was downloaded from the Gene Expression Omnibus database. The GSE53757 dataset contains tumor and matched paracancerous specimens from 72 ccRCC patients with clinical stage I to IV. The linear model of microarray data (limma) package in R language was used to identify differentially expressed genes (DEGs). The protein–protein interaction (PPI) network of the DEGs was constructed using the search tool for the retrieval of interacting genes (STRING). Subsequently, we visualized molecular interaction networks by Cytoscape software and analyzed modules with MCODE. A total of 1,284, 1,416, 1,610 and 1,185 up-regulated genes, and 932, 1,236, 1,006 and 929 down-regulated genes were identified from clinical stage I to IV ccRCC patients, respectively. The overlapping DEGs among the four clinical stages contain 870 up-regulated and 645 down-regulated genes. The enrichment analysis of DEGs in the top module was carried out with DAVID. The results showed the DEGs of the top module were mainly enriched in microtubule-based movement, mitotic cytokinesis and mitotic chromosome condensation. Eleven up-regulated genes and one down-regulated gene were identified as hub genes. Survival analysis showed the high expression of CENPE, KIF20A, KIF4A, MELK, NCAPG, NDC80, NUF2, TOP2A, TPX2 and UBE2C, and low expression of ACADM gene could be involved in the carcinogenesis, invasion or recurrence of ccRCC. Literature retrieval results showed the hub gene NDC80, CENPE and ACADM might be novel targets for the diagnosis, clinical treatment and prognosis of ccRCC. In conclusion, the findings of present study may help us understand the molecular mechanisms underlying the carcinogenesis and progression of ccRCC, and provide potential diagnostic, therapeutic and prognostic biomarkers.

Sign in / Sign up

Export Citation Format

Share Document